Drug Search Results
More Filters [+]

Vedroprevir

Alternative Names: vedroprevir, gs-9451, gs9451, gs 9451
Latest Update: 2018-11-16
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: HCV-NS3/4A Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Vedroprevir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis A|Hepatitis C, Chronic|Hepatitis C|Communicable Diseases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2011-000946-39

P2

Completed

Hepatitis C

2018-04-09

2011-000945-19

P2

Terminated

Hepatitis C

2017-11-30

13-I-0066

P2

Completed

Hepatitis A|Hepatitis C, Chronic

2015-08-01

GS-US-337-1512

P2

Completed

Communicable Diseases|Hepatitis C

2015-02-01

Recent News Events

Date

Type

Title